S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NYSE:RMED

Ra Medical Systems Competitors

$5.80
+0.05 (+0.87 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.18
Now: $5.80
$6.14
50-Day Range
$5.75
MA: $7.57
$8.97
52-Week Range
$4.25
Now: $5.80
$42.00
Volume274,339 shs
Average Volume394,694 shs
Market Capitalization$16.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

Ra Medical Systems (NYSE:RMED) Vs. PSTV, SSKN, SINT, MOTS, NVCN, and AEMD

Should you be buying RMED stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Ra Medical Systems, including Plus Therapeutics (PSTV), STRATA Skin Sciences (SSKN), Sintx Technologies (SINT), Motus GI (MOTS), Neovasc (NVCN), and Aethlon Medical (AEMD).

Ra Medical Systems (NYSE:RMED) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ra Medical Systems and Plus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
Plus Therapeutics00303.00

Ra Medical Systems currently has a consensus price target of $31.50, indicating a potential upside of 443.10%. Plus Therapeutics has a consensus price target of $7.00, indicating a potential upside of 150.00%. Given Ra Medical Systems' higher probable upside, research analysts clearly believe Ra Medical Systems is more favorable than Plus Therapeutics.

Volatility & Risk

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Institutional & Insider Ownership

7.0% of Plus Therapeutics shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Comparatively, 0.1% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and Plus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
Plus Therapeutics-24.23%-208.43%-21.41%

Valuation and Earnings

This table compares Ra Medical Systems and Plus Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
Plus Therapeutics$7 million8.44$-10,890,000.00N/AN/A

Plus Therapeutics has lower revenue, but higher earnings than Ra Medical Systems.

Summary

Plus Therapeutics beats Ra Medical Systems on 7 of the 13 factors compared between the two stocks.

Ra Medical Systems (NYSE:RMED) and STRATA Skin Sciences (NASDAQ:SSKN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ra Medical Systems and STRATA Skin Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
STRATA Skin Sciences00303.00

Ra Medical Systems currently has a consensus price target of $31.50, indicating a potential upside of 443.10%. STRATA Skin Sciences has a consensus price target of $4.25, indicating a potential upside of 150.00%. Given Ra Medical Systems' higher probable upside, research analysts clearly believe Ra Medical Systems is more favorable than STRATA Skin Sciences.

Volatility & Risk

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 2.45, indicating that its stock price is 145% more volatile than the S&P 500.

Institutional & Insider Ownership

24.5% of STRATA Skin Sciences shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Comparatively, 42.9% of STRATA Skin Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and STRATA Skin Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
STRATA Skin Sciences-17.68%-16.33%-9.57%

Valuation and Earnings

This table compares Ra Medical Systems and STRATA Skin Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
STRATA Skin Sciences$31.59 million1.82$-3,790,000.00($0.11)-15.45

STRATA Skin Sciences has higher revenue and earnings than Ra Medical Systems. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than Ra Medical Systems, indicating that it is currently the more affordable of the two stocks.

Summary

STRATA Skin Sciences beats Ra Medical Systems on 11 of the 14 factors compared between the two stocks.

Ra Medical Systems (NYSE:RMED) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ra Medical Systems and Sintx Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
Sintx Technologies00203.00

Ra Medical Systems currently has a consensus price target of $31.50, indicating a potential upside of 443.10%. Sintx Technologies has a consensus price target of $3.3750, indicating a potential upside of 79.52%. Given Ra Medical Systems' higher probable upside, research analysts clearly believe Ra Medical Systems is more favorable than Sintx Technologies.

Volatility & Risk

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

1.4% of Sintx Technologies shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Comparatively, 0.0% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and Sintx Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
Sintx Technologies-862.55%-39.83%-30.77%

Valuation and Earnings

This table compares Ra Medical Systems and Sintx Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
Sintx Technologies$690,000.0069.62$-4,800,000.00N/AN/A

Sintx Technologies has lower revenue, but higher earnings than Ra Medical Systems.

Summary

Sintx Technologies beats Ra Medical Systems on 7 of the 13 factors compared between the two stocks.

Ra Medical Systems (NYSE:RMED) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ra Medical Systems and Motus GI, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
Motus GI00503.00

Ra Medical Systems currently has a consensus price target of $31.50, indicating a potential upside of 443.10%. Motus GI has a consensus price target of $2.40, indicating a potential upside of 107.79%. Given Ra Medical Systems' higher probable upside, research analysts clearly believe Ra Medical Systems is more favorable than Motus GI.

Volatility & Risk

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Motus GI has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

Institutional & Insider Ownership

38.9% of Motus GI shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Comparatively, 18.1% of Motus GI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and Motus GI's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
Motus GI-12,916.77%-151.69%-77.43%

Valuation and Earnings

This table compares Ra Medical Systems and Motus GI's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
Motus GI$110,000.00338.53$-23,090,000.00($0.92)-1.26

Motus GI has lower revenue, but higher earnings than Ra Medical Systems. Motus GI is trading at a lower price-to-earnings ratio than Ra Medical Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Motus GI beats Ra Medical Systems on 9 of the 14 factors compared between the two stocks.

Ra Medical Systems (NYSE:RMED) and Neovasc (NASDAQ:NVCN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility & Risk

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Neovasc has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ra Medical Systems and Neovasc, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
Neovasc00403.00

Ra Medical Systems currently has a consensus price target of $31.50, indicating a potential upside of 443.10%. Neovasc has a consensus price target of $6.25, indicating a potential upside of 425.21%. Given Ra Medical Systems' higher probable upside, research analysts clearly believe Ra Medical Systems is more favorable than Neovasc.

Institutional & Insider Ownership

13.5% of Neovasc shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and Neovasc's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
Neovasc-1,823.10%N/A-239.38%

Valuation and Earnings

This table compares Ra Medical Systems and Neovasc's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
Neovasc$2.09 million16.49$-35,130,000.00($5.05)-0.24

Neovasc has lower revenue, but higher earnings than Ra Medical Systems. Neovasc is trading at a lower price-to-earnings ratio than Ra Medical Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Neovasc beats Ra Medical Systems on 8 of the 14 factors compared between the two stocks.

Ra Medical Systems (NYSE:RMED) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

Ra Medical Systems has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Aethlon Medical has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Ra Medical Systems and Aethlon Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ra Medical Systems02102.33
Aethlon Medical00103.00

Ra Medical Systems presently has a consensus price target of $31.50, indicating a potential upside of 443.10%. Aethlon Medical has a consensus price target of $6.00, indicating a potential upside of 214.14%. Given Ra Medical Systems' higher probable upside, analysts clearly believe Ra Medical Systems is more favorable than Aethlon Medical.

Institutional and Insider Ownership

2.7% of Aethlon Medical shares are held by institutional investors. 2.4% of Ra Medical Systems shares are held by insiders. Comparatively, 0.7% of Aethlon Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ra Medical Systems and Aethlon Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ra Medical Systems-772.04%-120.68%-85.93%
Aethlon MedicalN/A-55.32%-49.72%

Valuation & Earnings

This table compares Ra Medical Systems and Aethlon Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ra Medical Systems$7.20 million2.35$-56,960,000.00($108.25)-0.05
Aethlon Medical$650,000.0035.63$-6,390,000.00($1.87)-1.02

Aethlon Medical has lower revenue, but higher earnings than Ra Medical Systems. Aethlon Medical is trading at a lower price-to-earnings ratio than Ra Medical Systems, indicating that it is currently the more affordable of the two stocks.

Summary

Aethlon Medical beats Ra Medical Systems on 8 of the 13 factors compared between the two stocks.


Ra Medical Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Plus Therapeutics logo
PSTV
Plus Therapeutics
1.5$2.80+20.4%$59.10 million$7 million-2.77News Coverage
Gap Up
STRATA Skin Sciences logo
SSKN
STRATA Skin Sciences
1.5$1.70+2.4%$57.41 million$31.59 million-12.14Gap Up
SINT
Sintx Technologies
1.3$1.88+10.6%$48.04 million$690,000.00-0.80Increase in Short Interest
Gap Up
Motus GI logo
MOTS
Motus GI
1.5$1.16+4.3%$37.24 million$110,000.00-1.63
Neovasc logo
NVCN
Neovasc
1.4$1.19+4.2%$34.47 million$2.09 million-0.38Upcoming Earnings
Gap Up
Aethlon Medical logo
AEMD
Aethlon Medical
1.4$1.91+1.0%$23.16 million$650,000.00-1.02Gap Down
InVivo Therapeutics logo
NVIV
InVivo Therapeutics
0.7$1.09+16.5%$23.08 millionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Obalon Therapeutics logo
OBLN
Obalon Therapeutics
0.5$2.78+4.7%$21.60 million$3.28 million-1.35Upcoming Earnings
Decrease in Short Interest
Gap Up
LLIT
Lianluo Smart
0.5$8.15+15.7%$18.02 million$380,000.000.00Decrease in Short Interest
Gap Up
INVO Bioscience logo
INVO
INVO Bioscience
1.1$3.38+5.6%$16.75 million$1.48 million-3.55Gap Up
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.9$4.06+7.1%$16.66 million$24.08 million-0.48Increase in Short Interest
Gap Down
Hancock Jaffe Laboratories logo
HJLI
Hancock Jaffe Laboratories
0.5$6.40+3.3%$16.57 million$30,000.000.00Upcoming Earnings
Decrease in Short Interest
Gap Up
Dynatronics logo
DYNT
Dynatronics
1.3$1.07+2.8%$16.02 million$53.41 million-2.67
NeuroMetrix logo
NURO
NeuroMetrix
0.6$3.01+2.3%$11.43 million$9.27 million0.00Decrease in Short Interest
Cellect Biotechnology logo
APOP
Cellect Biotechnology
0.6$2.86+2.1%$6.41 millionN/A-1.59Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.